Tumor growth was significantly reduced in Bcl9-depleted tumors treated with anti-PD-1 antibody, compared to NT-shRNA tumors receiving anti-PD-1 alone, with a TGI of 81.8% by day 16 (Fig. 2a, b), while in the MC38 model with MSI, anti-PD-1 therapy displayed a TGI of 56.72%. The gene discussed is PDCD1; the disease is neoplasm.